Patient-Centered Psychopharmacology and Psychosocial Interventions: Treatment Selection and Shared Decision-Making to Enhance Chances for Recovery

In this CME activity, learn how to use patient-centered care to enhance medication adherence and aid functional recovery in schizophrenia.

Abstract

Individuals with schizophrenia can achieve the ultimate goal of treatment—recovery. However, patients are often nonadherent to prescribed medication regimens, leading to relapses and significantly decreasing their chances of ever reaching this goal. By implementing patient-centered assessment and evidence-based pharmacologic and psychosocial interventions, such as LAI antipsychotics, cognitive-behavioral therapy, and motivational interviewing, clinicians can improve medication adherence and enhance the potential for functional recovery.

From the Series: The Schizophrenia Remission Roller Coaster: Using Long-Acting Injectable Antipsychotics to Improve Adherence and Enhance Potential for Functional Recovery

To cite: Lauriello J. Patient-centered psychopharmacology and psychosocial interventions: treatment selection and shared decision-making to enhance chances for recovery. J Clin Psychiatry. 2020;81(3):MS19053BR4C.

To share: https://doi.org/10.4088/JCP.MS19053BR4C

© Copyright 2020 Physicians Postgraduate Press, Inc.

Target Audience

  • Psychiatrists, NPs/PAs

Learning Objectives

After completing this educational activity, you should be able to:

  • Incorporate nonpharmacologic therapies to optimize patients’ potential for functional recovery
  • Use guidelines, clinical characteristics, and a patient-centered approach to select medication treatment for patients with schizophrenia who often relapse
Activity summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
Activity opens: 
04/29/2020
Activity expires: 
04/30/2022
Cost:
$0.00
Rating: 
0

Support Statement

Supported by educational grants from Alkermes, Inc., Otsuka America Pharmaceutical, Inc. and Lundbeck.

Participants may receive credit by reading the activity, scoring 70% or higher on the posttest, and completing the evaluation.

Objective

After completing this educational activity, you should be able to:

  • Use guidelines, clinical characteristics, and a patient-centered approach to select medication treatment for patients with schizophrenia who often relapse
  • Incorporate nonpharmacologic therapies to optimize patients’ potential for functional recovery

Release, Review, and Expiration Dates

This brief report activity was published in April 2020 and is eligible for AMA PRA Category 1 Credit™ through April 30, 2022. The latest review of this material was March 2020.

Statement of Need and Purpose

The goals of schizophrenia treatment are to control symptoms, prevent relapse, and improve functioning and quality of life. For many patients, these goals are not being met. Evidence demonstrates that LAI antipsychotics are one of the most effective ways to prevent relapse in patients with schizophrenia, yet they remain underused. Health care providers infrequently discuss LAI antipsychotic options with their patients with schizophrenia. Clinicians also may overestimate adherence or not even assess it despite guideline recommendations. Patients with multiple relapses are often continued on oral medications, and few clinicians consider LAIs early in the course of illness. Health care providers need education on the efficacy, safety, and dosage/administration of LAIs, as well as on discussing LAIs with their patients.

Disclosure of Off-Label Usage

Dr Lauriello has determined that, to the best of his knowledge, no investigational information about pharmaceutical agents or device therapies that is outside US Food and Drug Administration–approved labeling has been presented in this activity.

Review Process

The faculty member agreed to provide a balanced and evidence-based presentation and discussed the topics and CME objectives during the planning sessions. The faculty’s submitted content was validated by CME Institute staff, and the activity was evaluated for accuracy, use of evidence, and fair balance by a peer reviewer who is without conflict of interest.

Acknowledgment

This activity is derived from the planning teleconference series “The Schizophrenia Remission Roller Coaster: Using Long-Acting Injectable Antipsychotics to Improve Adherence and Enhance Potential for Functional Recovery,” which was held in September and October 2019 and supported by educational grants from Alkermes and Otsuka and Lundbeck.

Faculty Affiliation

John Lauriello, MD
Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania

 

FINANCIAL DISCLOSURE

The faculty for this CME activity and the CME Institute staff were asked to complete a statement regarding all relevant personal and financial relationships between themselves or their spouse/partner and any commercial interest. The Accreditation Council for Continuing Medical Education (ACCME) defines a commercial interest as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. The CME Institute has resolved any conflicts of interest that were identified. No member of the CME Institute staff reported any relevant personal financial relationships. Faculty financial disclosure is as follows:

Dr Lauriello is a consultant for Alkermes and Indivior and a member of the speaker/advisory board for Roche.

The chair, Christoph U. Correll, MD, is a consultant for and has received honoraria from Acadia, Alkermes, Allergan, Angelini, Axsome, Boehringer-Ingelheim, Gedeon Richter, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Merck, Neurocrine, Noven, Otsuka, Pfizer, Recordati, ROVI, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva; has received grant/research support from Janssen and Takeda; is a member of the speakers/advisory boards for Alkermes, Allergan, Angelini, Gedeon Richter, IntraCellular Therapies, Janssen, LB Pharma, Lundbeck, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva; is a stock option holder of LB Pharma; and has received other financial or material support for expert testimony from Bristol-Myers Squibb, Janssen, and Otsuka and royalties from UpToDate.

 

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

 

 

CREDIT DESIGNATION

The CME Institute of Physicians Postgraduate Press, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

To obtain credit for this activity, study the material and complete the CME Posttest and Evaluation.

MOC APPROVAL STATEMENT

Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification DirectoryPatient-Centered Psychopharmacology and Psychosocial Interventions: Treatment Selection and Shared Decision-Making to Enhance Chances for Recovery has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

MOC PART II CME ACTIVITY

Psychiatry and Neurology

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation

Price

Cost:
$0.00
Please login or register to take this activity.

Register for free on our site to participate in this and many other free CME courses.